中國醫藥(600056.SH)協議今年負責輝瑞新冠口服藥運營
中國醫藥(600056.SH)與輝瑞公司(PFE.US)簽訂協議,將在2022年度(協議期內)負責輝瑞公司新冠病毒治療口服藥物奈瑪特韋片/利託那韋片組合包裝(PAXLOVID)在內地市場商業運營。該產品的最終使用及銷售情況受疫情防控等因素影響存在較大不確定性,預計相關業務規模佔公司整體業務量比重較小。
輝瑞公司同時公佈,與中國醫藥就新冠病毒治療口服藥物PAXLOVID簽訂供應協議。中國醫藥將在協議期內負責輝瑞公司新冠病毒治療藥物PAXLOVID在內地市場的商業運營。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.